INNOVADERM CRO IS NOW INDERO.
circle

Dr. Robert Bissonnette, EY Entrepreneur Of The Year® 2024 finalist

Ana Palijan, PhD

Ana Palijan, PhD

Director, Early Phase and Translational Research

2024-06-05

We are thrilled to announce that Dr. Robert Bissonnette, the visionary founder, and CEO of Innovaderm Research, has been shortlisted for the esteemed EY Entrepreneur Of The Year® 2024 award.

Dr. Bissonnette is a world-renowned key opinion leader in psoriasis and atopic dermatitis. His entrepreneurial spirit, curiosity, creativity, and analytical thinking have led Innovaderm to become the world’s largest privately owned dermatology specialized CRO. Under his leadership, Innovaderm has been recognized by the CRO Leadership Awards for 4 consecutive years, completed 500+ dermatology clinical trials which recruited 12,000+ subjects. His company has grown from a local entity in Montreal to a global organization with 400+ employees around the world.

His commitment to dermatology research is evident in his 200+ scientific peer-reviewed publications and his past role as a founding member of the International Eczema Council and his continuous patient care. His innovative approaches have led to the improvement of non-surgical techniques in sample collection and study designs.

But the adventure does not end here! The next step in this exciting process is an interview in front of a jury. This esteemed panel will select the Entrepreneur Of The Year 2024. Dr. Bissonnette will have the opportunity to showcase his vision, leadership, and the impact Innovaderm has made in the field of dermatology.

Join us in congratulating Dr. Bissonnette on this remarkable achievement.

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.

Site Selection & Management

Our long-standing relationships with key opinion leaders and highly performing sites, result in optimized start-up processes that deliver strong results in the least amount of time. As part of our site evaluation, our team utilizes past performance metrics, recruitment projections based on competitive landscape, and detailed feasibility surveys to determine a site’s capabilities and interest in a study.

Hands, tablet and contact us with healthcare marketing or advertising on a website in the medical industry.

Patient Recruitment

Our dedicated patient recruitment and advertising team integrates with the study team to tailor recruitment strategies, customize central ad campaigns, develop advertising creative, and continuously track and adapt recruitment goals. Our patient-centric approach is enhanced by Clinago, our technology enabled recruitment service.

PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including site selection process, budget and contract negotiations, and patient engagement, recruitment enrollment projections, all while respecting your study timelines.

PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including site selection process, budget and contract negotiations, and patient engagement, recruitment enrollment projections, all while respecting your study timelines.